Multicenter trial of L-Deprenylin Parkinson disease

  title={Multicenter trial of L-Deprenylin Parkinson disease},
  author={Stefano Ruggieri and Alessandro Denaro and Giuseppe Meco and Angelico Carta and Fabrizio Stocchi and Alessandro Agnoli},
  journal={The Italian Journal of Neurological Sciences},
A multicenter trial was conducted at 9 Neurology Departements to evaluate the action of L-Deprenyl, a specific monoamine oxidase-B inhibitor, combined with L-Dopa in the treatment of Parkinson disease. In all, 76 patients were treated, 33 women and 43 men, on stable treatment with L-Dopa+aromatic decarboxylase inhibitors (DI) for at least 6 months. After a 50% reduction of the L-Dopa dose, all received L-Deprenyl 5 mg twice daily for 35 day. The combined treatment resulted in a definite… 
1 Citations


Overview of present day treatment of Parkinson's disease
  • M. Yahr
  • Medicine, Biology
    Journal of Neural Transmission
  • 2005
Preliminary results in 35 patients indicate that Deprenyl, an MAO-B inhibitor, given with levodopa and carbidopa has shown the most promise and appears to be a valuable adjunctive agent for the long-term problem patient.
On the mode of action of L-deprenyl in the human central nervous system
In vitro studies demonstrated that (-)deprenyl in comparison to d, l-tranylcypromine, clorgyline and harmaline is by far the most potent inhibitor of human brain MAO, and long-term treatment with more than 1 mg/10 kg body weight could result in an accumulation of (-)DeprenylIn the brain.
“On‐off” phenomenon with levodopa therapy in parkinsonism
  • S. Fahn
  • Psychology, Medicine
  • 1974
Serial half-hourly measurements of plasma levels of dopa, 3-O-methyldopa, and homovanillic acid showed partial concordance between clinical fluctuation and plasma dopa levels in patients receiving levodopa alone or in combination with carbidopa.
On‐off response
Seven parkinsonian patients who had severe on-off effects during chronic treatment with levodopa were studied and central noradrenergic mechanisms as well as alterations in circulating dopa may contribute to the on- off response to levodOPA.
Depression and Parkinson's disease.
The estimated prevalence of depression in PD varies according to the type of mood assessment applied (interview versus self-report questionnaire), diagnostic criteria or definition of depression (the
Postural and resting tremors in Parkinson's disease.